Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/534 |
Resumo: | The therapeutic approach to severe pulmonary arterial hypertension (PAH), whether primary or secondary to connective tissue disorders, thromboembolic phenomena or congenital heart disease with Eisenmenger syndrome, has evolved in recent years following the introduction of selective pulmonary vasodilators, including prostacyclin analogs and endothelin receptor antagonists. AIM: To correlate three different endpoints (6-minute walk test, Tei index and peak tricuspid regurgitation velocity by Doppler echocardiographic study) during follow-up of PAH patients under selective vasodilator therapy. METHODS: Eleven patients (9 female, age 42 +/- 18 years) with severe PAH (> or = 65 mmHg), 64% with Eisenmenger syndrome, in NYHA class > or = II, were assessed during a follow-up of 11 +/- 8 months. Eight patients were already under therapy with iloprost or bosentan. RESULTS: There was no correlation between the three endpoints before and after therapy as assessed by Pearson's correlation coefficient. There was, however, an improvement in all of them after selective vasodilatory therapy. CONCLUSION: Therapeutic response can be accurately measured by the traditional endpoint (6-minute walk test) or by echocardiographic endpoints. However, the lack of correlation between them excludes their use as alternatives in patient follow-up. |
id |
RCAP_7f5b91a5e753781e88a5b7e2d57f1e6b |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/534 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de EndpointSelective Pulmonary Vasodilators for Severe Pulmonary Hypertension: Comparison Between EndpointsProva de EsforçoHipertensão PulmonarÍndice de Gravidade da DoençaVasodilatadoresHSM CARThe therapeutic approach to severe pulmonary arterial hypertension (PAH), whether primary or secondary to connective tissue disorders, thromboembolic phenomena or congenital heart disease with Eisenmenger syndrome, has evolved in recent years following the introduction of selective pulmonary vasodilators, including prostacyclin analogs and endothelin receptor antagonists. AIM: To correlate three different endpoints (6-minute walk test, Tei index and peak tricuspid regurgitation velocity by Doppler echocardiographic study) during follow-up of PAH patients under selective vasodilator therapy. METHODS: Eleven patients (9 female, age 42 +/- 18 years) with severe PAH (> or = 65 mmHg), 64% with Eisenmenger syndrome, in NYHA class > or = II, were assessed during a follow-up of 11 +/- 8 months. Eight patients were already under therapy with iloprost or bosentan. RESULTS: There was no correlation between the three endpoints before and after therapy as assessed by Pearson's correlation coefficient. There was, however, an improvement in all of them after selective vasodilatory therapy. CONCLUSION: Therapeutic response can be accurately measured by the traditional endpoint (6-minute walk test) or by echocardiographic endpoints. However, the lack of correlation between them excludes their use as alternatives in patient follow-up.Sociedade Portuguesa de CardiologiaRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEFeliciano, JCacela, DAgapito, ASousa, LPelicano, NJFiarresga, ATimóteo, ATOliveira, JAQuininha, J2011-12-15T16:38:57Z20052005-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/534porRev Port Cardiol. 2005 Mar;24(3):399-404info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:27:06Zoai:repositorio.chlc.min-saude.pt:10400.17/534Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:18:18.602211Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint Selective Pulmonary Vasodilators for Severe Pulmonary Hypertension: Comparison Between Endpoints |
title |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
spellingShingle |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint Feliciano, J Prova de Esforço Hipertensão Pulmonar Índice de Gravidade da Doença Vasodilatadores HSM CAR |
title_short |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
title_full |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
title_fullStr |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
title_full_unstemmed |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
title_sort |
Vasodilatadores Pulmonares Selectivos na Hipertensão Pulmonar Grave: Utilização de 3 Diferentes Tipos de Endpoint |
author |
Feliciano, J |
author_facet |
Feliciano, J Cacela, D Agapito, A Sousa, L Pelicano, NJ Fiarresga, A Timóteo, AT Oliveira, JA Quininha, J |
author_role |
author |
author2 |
Cacela, D Agapito, A Sousa, L Pelicano, NJ Fiarresga, A Timóteo, AT Oliveira, JA Quininha, J |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Feliciano, J Cacela, D Agapito, A Sousa, L Pelicano, NJ Fiarresga, A Timóteo, AT Oliveira, JA Quininha, J |
dc.subject.por.fl_str_mv |
Prova de Esforço Hipertensão Pulmonar Índice de Gravidade da Doença Vasodilatadores HSM CAR |
topic |
Prova de Esforço Hipertensão Pulmonar Índice de Gravidade da Doença Vasodilatadores HSM CAR |
description |
The therapeutic approach to severe pulmonary arterial hypertension (PAH), whether primary or secondary to connective tissue disorders, thromboembolic phenomena or congenital heart disease with Eisenmenger syndrome, has evolved in recent years following the introduction of selective pulmonary vasodilators, including prostacyclin analogs and endothelin receptor antagonists. AIM: To correlate three different endpoints (6-minute walk test, Tei index and peak tricuspid regurgitation velocity by Doppler echocardiographic study) during follow-up of PAH patients under selective vasodilator therapy. METHODS: Eleven patients (9 female, age 42 +/- 18 years) with severe PAH (> or = 65 mmHg), 64% with Eisenmenger syndrome, in NYHA class > or = II, were assessed during a follow-up of 11 +/- 8 months. Eight patients were already under therapy with iloprost or bosentan. RESULTS: There was no correlation between the three endpoints before and after therapy as assessed by Pearson's correlation coefficient. There was, however, an improvement in all of them after selective vasodilatory therapy. CONCLUSION: Therapeutic response can be accurately measured by the traditional endpoint (6-minute walk test) or by echocardiographic endpoints. However, the lack of correlation between them excludes their use as alternatives in patient follow-up. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005 2005-01-01T00:00:00Z 2011-12-15T16:38:57Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/534 |
url |
http://hdl.handle.net/10400.17/534 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Rev Port Cardiol. 2005 Mar;24(3):399-404 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Cardiologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Cardiologia |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131279543762944 |